期刊文献+

终点HBsAg定量与普通干扰素治疗慢性乙肝停药1年内复发的相关性分析

Correlation analysis of terminal HBsAg quantity and the recurrence within 1 year of chronic hepatitis b treated with ordinary interferon
下载PDF
导出
摘要 目的:比较治疗终点(停药)HBs Ag定量,分析终点HBs Ag定量与普通干扰素治疗慢性乙肝1年内复发的相关性。方法:2009年1月-2013年6月收治慢性乙型肝炎患者90例,分为复发组和无复发组,比较两组停药时HBs Ag定量的不同。结果:复发组停药时HBs Ag定量较高,两组比较差异具有统计学意义(P<0.05)。结论:普通干扰素治疗慢性乙肝达到治疗终点时HBs Ag定量的高低与停药后1年内复发率存在明显的正相关性。普通干扰素治疗慢性乙型肝炎停药时HBs Ag的水平是推断治疗后1年内复发的有效预测指标。 Objective:To compare the treatment terminal HBsAg quantity and analyze the correlation of terminal HBsAg quantity and the recurrence within 1 year of chronic hepatitis b treated with ordinary interferon.Methods:90 cases of patients with chronic hepatitis b from January 2009 to June 2013 were divided into the relapse group and the no-relapse group and the differences of HBsAg quantity in the two groups were compared.Results:The terminal HBsAg quantity of the relapse group was higher,there was statistically significant difference between the two groups(P<0.05).Conclusion:The terminal HBsAg quantity of chronic hepatitis b treated by ordinary interferon had obviously positive correlation with the recurrence rate within 1 year.The terminal HBsAg quantity of chronic hepatitis b treated by ordinary interferon was inferred effective predictors of recurrence within 1 year after treatment.
作者 陈晓辉 边城 Chen Xiaohui;Bian Cheng(The Medical College in Qingdao University(the people's hospital of hanting district in weifang) 261100;The first hospital affiliated to medical school in Qingdao university 266011)
出处 《中国社区医师》 2015年第13期76-77,共2页 Chinese Community Doctors
关键词 终点HBsAg定量 慢性乙型肝炎 普通干扰素 复发 相关性分析 Terminal HBsAg quantitative Chronic hepatitis b Ordinary interferon Recurrence Correlation analysis
  • 相关文献

参考文献2

二级参考文献17

  • 1慢性乙型肝炎防治指南[J].中华传染病杂志,2005,23(6):421-431. 被引量:824
  • 2姚光弼,朱玫,马秀云,蔡皓东.拉米夫定治疗HBeAg阳性慢性乙型肝炎患者7年结果总结[J].肝脏,2007,12(2):81-86. 被引量:26
  • 3骆抗先.实验感染模型[A].骆抗先主编.乙型肝炎基础和临床:第2版[C].北京:人民卫生出版社,2001.74-84.
  • 4Ahn SH, Chan HL, Chen PJ, et al. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int, 2010,4.386-395.
  • 5Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int,2008,2 .263-283.
  • 6Lok AS, MeMahon BJ. ChroMe hepatitis B: update 2009. Hepatology, 2009,50:661 662.
  • 7European Association for the Study of the Liver. EASI. Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol, 2009,501227-242.
  • 8Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follfoow-up of patients with anti HBe/HBV DNA-positive chronic hepatitis B treated r 12 months with lamivudine. J Hepatol, 2000,32:300 -306.
  • 9Lee HC, Suh DJ, Ryu SH, et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut, 2003,52: 1779-1783.
  • 10Byun KS, Kwon OS, Kim JH, et al. Factors related to post-treatment relapse in chronic hepatitis B patients who lost I-tBeAg after lamivudine therapy. J Gastroenterol Hepatol, 2005,20 : 1838-1842.

共引文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部